|
|
||||||||
|
FIGURE 3. Ratios of 177Lu-DOTATATE and 111In-octreotide uptake in tumor sites. Uptake was expressed as percentage of administered dose. Note differences in uptake between patients with HCTC who responded with MRe and PR and those who did not respond with tumor shrinkage.
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |